請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59387
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蕭斐元 | |
dc.contributor.author | Shih-Tsung Huang | en |
dc.contributor.author | 黃世宗 | zh_TW |
dc.date.accessioned | 2021-06-16T09:22:13Z | - |
dc.date.available | 2022-09-08 | |
dc.date.copyright | 2017-09-08 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-06-27 | |
dc.identifier.citation | 1. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and Psychological Symptoms of Dementia. Front Neurol 2012;3.
2. Beck CA, Williams JV, Wang JL, et al. Psychotropic medication use in Canada. Can J Psychiatry 2005;50:605-13. 3. Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011;183:E411-9. 4. U.S. Food and Drug Administration. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. (Accessed May 31, 2017, at https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm.) 5. Health Canada. Health canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. (Accessed May 31, 2017, at http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/13696a-eng.php.) 6. U.S. Food and Drug Administration. Information for healthcare professionals: conventional antipsychotics. (Accessed May 31, 2017, at https://www.fda.gov/Drugs/DrugSafety/ucm124830.htm.) 7. 財團法人藥害救濟基金會。衛生署公告:關於抗精神病藥物之仿單應加警語事宜. (Accessed May 31, 2017, at http://www.tdrf.org.tw/ch/03_message/mes_02_main.asp?bull_id=3763.) 8. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010;67:26-36. 9. World Health Organization. Psychoactive substances. (Accessed May 31, 2017, at http://www.who.int/substance_abuse/terminology/psychoactive_substances/en/.) 10. World Health Organization. Psychotropic medications. (Accessed May 31, 2017, at http://www.emro.who.int/health-topics/psychotropic-medications/index.html.) 11. Hsiao FY, Peng LN, Lin MH, Chen LK. Dose-responsive effect of psychotropic drug use and subsequent dementia: a nationwide propensity score matched case-control study in Taiwan. J Am Med Dir Assoc 2014;15:509-13. 12. Johnell K, Jonasdottir Bergman G, Fastbom J, Danielsson B, Borg N, Salmi P. Psychotropic drugs and the risk of fall injuries, hospitalisations and mortality among older adults. Int J Geriatr Psychiatry 2017;32:414-20. 13. Chien IC, Bih SH, Chou YJ, Lin CH, Lee WG, Chou P. Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004. Psychiatr Serv 2007;58:554-7. 14. Alonso F, Esteban C, Montoro L, Tortosa F. Psychotropic drugs and driving: prevalence and types. Ann Gen Psychiatry 2014;13:14. 15. Boyd A, Van de Velde S, Pivette M, et al. Gender differences in psychotropic use across Europe: Results from a large cross-sectional, population-based study. Eur Psychiatry 2015;30:778-88. 16. Richter T, Mann E, Meyer G, Haastert B, Kopke S. Prevalence of psychotropic medication use among German and Austrian nursing home residents: a comparison of 3 cohorts. J Am Med Dir Assoc 2012;13:187 e7- e13. 17. Téllez-Lapeira J, López-Torres Hidalgo J, García-Agua Soler N, Gálvez-Alcaraz L, Escobar-Rabadán F, García-Ruiz A. Prevalence of psychotropic medication use and associated factors in the elderly. The European Journal of Psychiatry 2016;30:183-94. 18. Frenk SM, Sautter JM, Paulose-Ram R. Prevalence and trends in psychotropic medication use among US male veterans, 1999-2010. Pharmacoepidemiol Drug Saf 2015;24:1215-9. 19. Crismon ML, Argo TR, Buckley PF. Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach 7th Edition: McGraw-Hill Publishing; 2008. 20. Dopp JM, Phillips BG. Sleep Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach 7th Edition: McGraw-Hill Publishing; 2008. 21. Drayton SJ, Weinstein B. Bipolar Disorder. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach 7th Edition: McGraw-Hill Publishing; 2008. 22. Kirkwood CK, Makela EH, Wells BG. Anxiety Disorders II: Posttraumatic Stress Disorder and Obsessive-Compulsive Disorder. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach 7th Edition: McGraw-Hill Publishing; 2008. 23. Kirkwood CK, Melton ST. Anxiety Disorders I: Generalized Anxiety, Panic, and Social Anxiety Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach 7th Edition: McGraw-Hill Publishing; 2008. 24. Teter CJ, Kando JC, Wells BG, Hayes PE. Depressive Disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach 7th Edition: McGraw-Hill Publishing; 2008. 25. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76. 26. Sergi G, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? Drugs Aging 2011;28:509-18. 27. By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015;63:2227-46. 28. Health Canada. Archived-important drug safety information: Risperdal (risperidone) and cerebrovascular adverse events in placebo-controlled dementia trials. (Accessed May 31, 2017, at http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/13696a-eng.php.) 29. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70. 30. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. 31. Health canada. Archived-important drug safety information: Zyprexa (olanzapine) and cerebrovascular adverse events in placebo-controlled elderly dementia trials. (Accessed May 31, 2017, at http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2004/14300a-eng.php.) 32. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353:2335-41. 33. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32. 34. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-86. 35. Almeida OP, Alfonso H, Hankey GJ, Flicker L. Depression, antidepressant use and mortality in later life: the Health In Men Study. PLoS One 2010;5:e11266. 36. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551. 37. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 2016;81:773-83. 38. Zivin K, Kim HM, Yosef M, et al. Antidepressant Medication Treatment and Risk of Death. J Clin Psychopharmacol 2016;36:445-52. 39. Haukka J, Arffman M, Partonen T, et al. Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort. Eur J Clin Pharmacol 2009;65:715-20. 40. Alamo C, Lopez-Munoz F, Garcia-Garcia P, Garcia-Ramos S. Risk-benefit analysis of antidepressant drug treatment in the elderly. Psychogeriatrics 2014;14:261-8. 41. Parsaik AK, Mascarenhas SS, Khosh-Chashm D, et al. Mortality associated with anxiolytic and hypnotic drugs-A systematic review and meta-analysis. Aust N Z J Psychiatry 2016;50:520-33. 42. Taipale HT, Bell JS, Hartikainen S. Sedative load among community-dwelling older individuals: change over time and association with mortality. Int Clin Psychopharmacol 2012;27:224-30. 43. Dauphinot V, Faure R, Omrani S, et al. Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort. J Clin Psychopharmacol 2014;34:565-70. 44. Lan TY, Zeng YF, Tang GJ, et al. The Use of Hypnotics and Mortality--A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0145271. 45. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009;70:1340-7. 46. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012;344:e977. 47. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015;72:438-45. 48. Sahlberg M, Holm E, Gislason GH, Kober L, Torp-Pedersen C, Andersson C. Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons. J Am Heart Assoc 2015;4:e001666. 49. Fulton MM, Allen ER. Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract 2005;17:123-32. 50. Wu YH, Chen CC, Wu TY. Geriatric polypharmacy in Taiwan. J Formos Med Assoc 2016;115:891-2. 51. Frandsen R, Baandrup L, Kjellberg J, Ibsen R, Jennum P. Increased all-cause mortality with psychotropic medication in Parkinson's disease and controls: a national register-based study. Parkinsonism Relat Disord 2014;20:1124-8. 52. Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociological methods & research 2001;29:374-93. 53. Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 2010;6:109-38. 54. Nagin DS. Group-based trajectory modeling: an overview. Ann Nutr Metab 2014;65:205-10. 55. 余民寧. 書評: 潛在成長曲線模式. 當代教育研究季刊 2013;21:149-59. 56. National Health Insurance Research Database, Taiwan. (Accessed May 31, 2017, at http://nhird.nhri.org.tw/en/index.htm.) 57. 鄭淑文, 楊瑛碧. 精神科門診 Benzodiazepine (BZDs) 使用現況初探. 藥學雜誌 2009;25:118-25. 58. Traj: group-based modeling of longitudinal data - Andrew.cmu.edu. (Accessed May 31, 2017, at https://www.andrew.cmu.edu/user/bjones/.) 59. 陳世雄, 胡百敏, 廖浩欽, 廖訓禎. 以全民健康保險研究資料庫之抽樣歸人檔資料分析急診病人就醫後流向. 台灣急診專科醫師期刊 2009;1:11-21. 60. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170:244-56. 61. Berry SD, Ngo L, Samelson EJ, Kiel DP. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc 2010;58:783-7. 62. Vidal X, Agusti A, Vallano A, et al. Elderly patients treated with psychotropic medicines admitted to hospital: associated characteristics and inappropriate use. Eur J Clin Pharmacol 2016;72:755-64. 63. Maust DT, Oslin DW, Marcus SC. Effect of age on the profile of psychotropic users: results from the 2010 National Ambulatory Medical Care Survey. J Am Geriatr Soc 2014;62:358-64. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/59387 | - |
dc.description.abstract | 研究背景:老年人長期精神藥物之多重用藥的問題與其臨床不良結果的相關性近年來十分受到關注。然而綜觀過去文獻,多數研究以單一類別精神藥物為主並採用橫斷性設計,未能考量用藥隨時間變動的特性,以及同時使用其他精神藥物的影響及整體精神藥物的劑量累積效應,然而這些因素都可能會影響精神藥物與臨床不良結果相關性的判讀。
研究目的:使用群組化軌跡模型分析新使用精神藥物之老年族群,在用藥隨時間變化影響下,有哪些不同的長期精神藥物使用模式(5年),比較不同使用模式之間的族群特性與精神藥物使用狀況的差異,並探討不同使用模式與臨床不良結果之相關性。 研究方法:本研究為一回溯性世代研究設計,利用台灣健保資料庫的老年特殊需求檔,篩選2004年內年滿65歲(含)新使用口服精神藥物的門診病人作為研究對象。本研究定義研究對象自新使用精神藥物起的五年為軌跡觀察期,先分析研究對象於軌跡觀察期前一年住院次數、共病症以了解每位研究對象之背景資料,之後以定義每日劑量為單位,紀錄研究對象於軌跡觀察期間每月精神藥物的使用量,並以軌跡化群組模式進行分析,找出研究族群有幾種不同的長期精神藥物使用模式後,依據分析結果進行分組。為了能完整記錄軌跡觀察期的精神藥物使用狀況,若研究對象於軌跡觀察期間死亡者則予以排除。分組完成後,以軌跡觀察期結束後三年作為不良結果觀察期,本研究之臨床不良結果為全死因死亡與非預期性住院事件,使用Kaplan-Meier survival curves及Cox proportional hazard model進行分析,探討不同長期精神藥物使用模式與臨床不良結果的相關性。 研究結果:本研究共納入39803位於門診新使用口服精神藥物的老年人,經群組化軌跡模式分析後,研究族群長期精神藥物使用模式可分為五組,分別為infrequent users (51.61 %)、increasing users(15.67 %)、decreasing users(13.45 %)、continued users(12.14 %)、sustained intense users(7.13 %)。 分析第一筆精神藥物處方,以鎮靜安眠藥物的開方比例最高,占57.92 %。進一步分析開方科別與相關診斷發現,任一組別皆有超過90 %的處方由非精神科專科醫師開出,並且該筆處方上未有任何精神疾病或失眠相關診斷者超過80 %。 精神藥物使用之長期趨勢方面,sustained intense users在軌跡觀察期間使用精神藥物的時間最長,其中又以鎮靜安眠藥物者的使用時間最長,達24.39個月。分析整體族群精神藥物多重用藥趨勢,有40.44 %的人曾併用兩種精神藥物,8.64 %的人曾併用三種精神藥物,若比較五個組別間差異,皆以sustained intense users比例最高,併用兩種有85.81 %,併用三種有44.77 %,並且大部分都是同時使用benzodiazepine及z-drug兩種鎮靜安眠藥物為主 不論在一年或三年觀察期中,皆發現長期精神藥物使用模式與全死因死亡及非預期性住院事件有正相關性,以infrequent users作為對照組時,sustained intense users發生兩種事件的風險皆為最高(1-year unplanned hospitalization: HR=1.38 (95 % CI: 1.23-1.55); 1-year death HR=1.26 (95 % CI: 1.08-1.48); 3-year unplanned hospitalization: HR=1.35 (95 % CI: 1.25-1.45); 3-year death HR=1.28 (95 % CI: 1.16-1.39)) 研究結論:台灣地區老年族群其長期精神藥物使用模式可分為五種,各模式間在族群特性、長期精神藥物使用趨勢皆有差異,因此在老年族群不能僅以短期精神藥物使用狀況來推測長期趨勢。長期精神藥物使用模式顯示與非預期性住院事件及全死因死亡有正相關性,其中又以sustained intense users風險最高,因此針對這群老人需要特別密切注意不良事件的發生,並且積極介入進行用藥評估。 | zh_TW |
dc.description.abstract | Background: Serious concerns regarding long-term use of multiple psychotropic agents (or psychotropic polypharmacy) in the elderly have been raised considering their vulnerability to psychotropic agents-associated adverse effects, such as hospitalization or mortality. However, existing studies on the use of psychotropic agents in the elderly are limited to cross-sectional design, one-time measurement of drug-exposure, or focusing on single category of psychotropic agent. In addition, no study has investigated the cumulative dose effect.
Objectives: This study aims to identify distinct trajectories of longitudinal psychotropic agents use and to examine the association between risk of mortality and unplanned hospitalization, according to distinct trajectories. Method: Adult who aged 65 years or older and newly initiated their oral psychotropic agents in 2004 were identified from Taiwan’s National Health Insurance Research Database. The date of first prescription of psychotropic agents was defined as the index date for each identified subject. Monthly consumption of psychotropic agents by defined daily dose (DDD) during the 5 years of follow-up since index date were retrieved. Group-based trajectory modeling with a zero-inflated Poisson distribution and third order polynomials was used to identify distinct group of longitudinal psychotropic agents use over 5 years. Clinical adverse outcomes of interest were unplanned hospitalization and all-cause mortality. Kaplan-Meier survival curves and Cox proportional hazard model were used to examine the association between distinct trajectories of longitudinal psychotropic agents use and clinical adverse outcomes. Result: Of the 54192 eligible older people, we identified 5 trajectories of longitudinal psychotropic agents use over a 5-year follow-up: sustained intense users (7.13 %), continued users (12.14 %), decreasing users (13.45 %), increasing users (15.67 %), and infrequent users (51.61 %). Most of the elderly used sedative drug as their first psychotropic agents (57.92 %). More than 90 % elderly get their first psychotropic agents from non-psychiatrist and more than 80 % of them were without any diagnosis of mental illness or insomnia. The pattern of long-term psychotropic agents use were different between trajectories groups. Sustained intense users had the longest time of using psychotropic agents, especially when they were using sedative drugs during the 5 years of follow-up since index date. About psychotropic polypharmacy, 85.81 % sustained intense users had been used 2 psychotropic agents, at the same time and 44.77 % of them had been used 3 psychotropic agents at the same time. The most common combination were a benzodiazepine and a z-drug. The positive associations between unplanned hospitalization and all-cause mortality and different trajectories were statistically significant, after adjusting age, sex and baseline comorbidities (1-year unplanned hospitalization: HR=1.38 (95 % CI: 1.23-1.55); 1-year death HR=1.26 (95 % CI: 1.08-1.48); 3-year unplanned hospitalization: HR=1.35 (95 % CI: 1.25-1.45); 3-year death HR=1.28 (95 % CI: 1.16-1.39)). Conclusion: we identified 5 distinct trajectories of longitudinal psychotropic agents use in the elderly in Taiwan and the psychotropic polypharmacy is very common in Taiwanese elderly, especially for those sustained intense users. Sustained intense users was associated with highest risks of death and unplanned hospitalization. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T09:22:13Z (GMT). No. of bitstreams: 1 ntu-106-R05451004-1.pdf: 2314461 bytes, checksum: 6326719757800351a7ab4af1412fb2e9 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iv 目錄 vii 表目錄 x 圖目錄 xii 第一章 緒論 1 第一節 研究背景 1 第二節 研究目的 2 第二章 文獻回顧 3 第一節 精神藥物之基本介紹 3 2.1.1 精神藥物之定義 3 2.1.2精神藥物之盛行率 3 2.1.3精神藥物之臨床應用與常見不良結果 4 第二節 精神藥品使用於老年族群之不良結果文獻回顧 6 第三節 老年人精神藥物多重用藥 20 2.3.1 老年人多重用藥問題 20 2.3.2 精神藥物多重用藥及相關趨勢 20 2.3.3 老年人精神藥物多重用藥與長期不良結果之相關性 21 第四節 群組化軌跡模式 24 第三章 研究方法 26 第一節 研究材料 26 第二節 研究設計 27 3.2.1 研究族群的納入與排除條件 29 3.2.2 研究藥物及長期用藥紀錄 31 3.2.3群組化軌跡模式的建立與分組 34 3.2.4追蹤期間定義 36 3.2.4研究終點定義 36 第三節 研究架構與研究變項 38 第四節 統計分析 42 3.4.1描述性統計 42 3.4.2推論性統計 42 第四章 研究結果 43 第一節 研究族群的建立 43 第二節 群組化軌跡模式分析結果 45 第三節 研究族群基本特質描述 50 第四節 軌跡追蹤期間精神藥物使用之長期趨勢 59 4.4.1各類精神藥物平均使用長度 59 4.4.2各組精神藥物使用歷程 63 4.4.3精神藥物多重用藥趨勢 73 第五節 追蹤期間不良結果發生情形 76 第六節 精神藥物長期使用模式與不良結果之相關性 79 4.6.1非預期性住院事件 80 4.6.2死亡事件 81 第五章 討論 85 第一節 不同精神藥物使用模式在族群基本特性的差異 86 第二節 老人精神藥物使用趨勢分析 89 第三節 精神藥物長期使用模式與不良結果之相關性分析 91 5.3.1非預期住院事件 91 5.3.2死亡事件 92 第六章 研究優點與限制 94 第一節 研究特色 94 第二節 研究限制 95 6.2.1研究資料 95 6.2.2研究樣本 95 6.2.3研究終點 95 6.2.3研究變項與測量 95 第七章 結論與建議 97 附錄 99 參考文獻 101 | |
dc.language.iso | zh-TW | |
dc.title | 以群組化軌跡模式分析老年族群之長期精神用藥趨勢及相關不良結果 | zh_TW |
dc.title | A Group Based Trajectory Analysis of Longitudinal Psychotropic Agents Use and Associated Adverse Outcomes in the Elderly | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳亮恭,高淑芬,溫有汶 | |
dc.subject.keyword | 精神藥物多重用藥,精神藥物,群組化軌跡模式,死亡,住院, | zh_TW |
dc.subject.keyword | psychotropic polypharmacy,psychotropic agents,group based trajectory model,mortality,hospitalization, | en |
dc.relation.page | 105 | |
dc.identifier.doi | 10.6342/NTU201701127 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-06-27 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.26 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。